Close Menu

Marc Tessier-Lavigne, the executive vice president for research and the chief scientific officer at Genentech, is leaving the company to take the helm of Rockefeller University in New York, reports the New York Times. Tessier-Lavigne will take up the position in March, succeeding Paul Nurse, who is returning to the UK to lead the Royal Society there.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.